Skip to content

Released May 10, 2018, after the close

10-Q filed May 10, 2018, 40 days after period end · 0001564590-18-012939

Q1 2018 · 10-Q
Revenue$1.03M−0.1% vs Q1 2017−0.1% vs Q4 2017
Net Income-$14.14MN/M vs Q1 2017N/M vs Q4 2017
EPS Diluted-$0.27N/M vs Q1 2017N/M vs Q4 2017
Operating Income-$14,054,000N/M
Operating Cash Flow-$12,551,000N/M
Free Cash Flowderived-$12,735,000N/M
Margins · derived
Operating margin-1369.8%−398.9 pt vs Q1 2017
Net margin-1377.7%−391.7 pt vs Q1 2017

What the release said

The release

Same quarter

MetricQ1 2018Q1 2017Q1 2016Q1 2015
Revenue$1.03M$1.03M$1.32M—
Net Income-$14.14M-$10.13M-$8.38M-$7.88M
EPS Diluted-$0.27-$0.24-$0.29-$0.38

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR